Stereotaxis
Stereotaxis develops robotic magnetic navigation systems and proprietary catheters for minimally invasive cardiac ablation, serving 100+ hospitals globally through direct enterprise sales supplemented by recurring catheter consumables and emerging digital surgery software.
- Company typePublic
- Founded1990
- HeadquartersSt Louis, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stereotaxis does
Stereotaxis is a St. Louis-based medical technology company founded in 1990 that develops robotic systems for minimally invasive endovascular procedures, with its primary application in cardiac ablation to treat arrhythmias. Its core technology, Robotic Magnetic Navigation (RMN), uses computer-controlled magnetic fields to navigate catheters inside the heart with precision, stability, and reduced radiation exposure, differentiating it from manual catheter ablation. The company sells capital equipment — the Genesis RMN System and the newer semi-mobile GenesisX System — to hospitals and electrophysiology labs globally. These systems are complemented by a proprietary consumable catheter portfolio (MAGiC ablation catheter, MAGiC Sweep high-density mapping catheter, and Map-iT diagnostic catheters acquired via the 2024 Access Point Technologies deal) that drives recurring procedure-based revenue under a razor/razor-blade model. More recently, Stereotaxis has expanded into a digital surgery ecosystem with the Synchrony platform (FDA-cleared April 2026), which aggregates cath lab systems onto a consolidated 4K display, and the SynX cloud app for HIPAA/GDPR-compliant remote connectivity, training, and collaboration, opening a subscription revenue stream. Customers are hospitals and electrophysiology labs across more than 100 sites in the US, Europe, and Asia, sold through a direct enterprise field sales force supplemented by a strategic partnership with Shanghai MicroPort EP Medtech for China.
The business model combines one-time capital equipment sales, recurring single-use catheter consumables, and emerging subscription software revenue. The company is unprofitable but improving — operating losses narrowed to approximately ($22.1M) in 2025 from ($24.7M) in 2024 on revenue of $32.4M (up 20% YoY), with 2026 guidance above $40M. Capital has been raised through a $15M Consonance Capital financing in 2020, a $12.5M registered direct offering in July 2025, and a $50M ATM facility with Roth Capital in August 2025. The announced acquisition of Robocath (April 2026, up to $45M) would extend the platform into interventional cardiology and neurointerventions, and a collaboration with CardioFocus (October 2025) targets robotic Pulsed Field Ablation, a next-generation energy modality. CEO David Fischel has led the company since 2019 under a Tesla-inspired performance-based compensation structure.
Stereotaxis firmographics
Firmographics- Name
- Stereotaxis
- Legal name
- Stereotaxis, Inc.
- Website
- https://stereotaxis.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Stereotaxis develops robotic magnetic navigation systems and proprietary catheters for minimally invasive cardiac ablation, serving 100+ hospitals globally through direct enterprise sales supplemented by recurring catheter consumables and emerging digital surgery software.
- Ownership category
- akta.pro rank
Stereotaxis industry classification
Industry- Product category
- Surgical Robotics for Cardiac Electrophysiology
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industries
- Healthcare & Assistive Robotics (HDAAAIAC), Remote Patient Monitoring (RPM) Platforms & Device Hubs (Connectivity/Gateways) (HLAHACAH)
Keywords
Where Stereotaxis is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Stereotaxis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Robotic Surgical Systems: Capital equipment sales of Genesis and GenesisX robotic magnetic navigation systems to hospitals. Systems represent significant upfront capital expenditure for hospital cath labs.
- Catheter Consumables: Recurring revenue from proprietary ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in procedures with robotic systems. Razor/razor-blade model driving recurring consumable sales.
- Digital Surgery Software/Services: Revenue from Synchrony digital surgery platform and SynX cloud connectivity services. Company expects more than $3 million in standalone SynX revenues.
- Stock Sales (ATM Facility): Sales Agreement with Roth Capital Partners allowing sale of up to $50 million worth of common stock for working capital, R&D, and commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Capital equipment - Robotic systems |
| Unit Pricing | Pay-as-you-go | Catheter consumables |
| Subscription | Annual | SynX cloud connectivity |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels12 records
Stereotaxis product offering
Product offeringCore offering
Stereotaxis develops and sells Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—that use computer-controlled magnetic fields to navigate electrophysiology catheters inside the heart with precision and stability. The company also sells proprietary single-use ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in conjunction with the robotic systems, as well as the Synchrony digital surgery platform and SynX cloud connectivity app. These offerings are sold primarily to hospitals and cardiac electrophysiology labs for minimally invasive treatment of arrhythmias and coronary artery disease.
Product overview
Stereotaxis is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. The company's portfolio centers on Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—which use computer-controlled magnetic fields to precisely navigate catheters during cardiac ablation procedures. Complementing the robotic systems are differentiated catheters including MAGiC ablation catheters, MAGiC Sweep mapping catheters, and Map-iT diagnostic catheters (from the Access Point Technologies acquisition). The Synchrony digital surgery platform aggregates cath lab systems onto consolidated 4K displays, paired with the cloud-based SynX app for remote connectivity and collaboration. Together, these products form a comprehensive ecosystem addressing the interventional laboratory from robotic navigation to digital surgery enablement.
Differentiator
Problem solved
Functional benefit
Brands
- Genesis: Robotic Magnetic Navigation System - designed as a powerful robotic magnetic navigation system with unprecedented responsiveness to physician control
- GenesisX
- Synchrony
- SynX
- MAGiC
- MAGiC Sweep
- Map-iT
- Cardiodrive
- Navigant
Products and services
- Genesis Robotic Magnetic Navigation System The most powerful Robotic Magnetic Navigation System by Stereotaxis, featuring magnets held on flexible robotic arms for unprecedented physician control, increased system angulation, and improved performance and reliability compared to prior RMN systems. Sold as capital equipment to hospitals with electrophysiology labs.
- GenesisX Robotic Magnetic Navigation System Next-generation semi-mobile Robotic Magnetic Navigation System combining Genesis speed and responsiveness with a form factor deployable in a cath lab over a weekend with no lab modifications required. Magnetic fields are shielded within the base when parked, allowing unrestricted use of the room.
- Synchrony System Digital surgery platform that aggregates all cath lab systems and procedural information onto a consolidated 55-inch 4K ultra-high-definition display. Enables complete control of disparate systems through a single keyboard and mouse, declutters the lab environment, and supports future technological integration.
- SynX Cloud-Based System Cloud-based app integrating with Synchrony display system for high-fidelity low-latency transmission of all lab information. Enables remote procedure monitoring, training, support, and collaboration in HIPAA/GDPR-compliant fashion requiring minimal hardware.
- MAGiC Magnetic Interventional Ablation Catheter The world's first robotically navigated magnetic RF ablation catheter. Used with Stereotaxis robotic systems to provide catheter precision, stability, and flexibility for diagnosing and treating cardiac arrhythmias. Sold as single-use consumable driving recurring razor-blade revenue.
- MAGiC Sweep Mapping Catheter The world's first robotically navigated high-density EP mapping catheter with 20 electrodes for rapid and highly detailed electroanatomical mapping. Enables mapping of complex anatomy with the inherent safety of an atraumatic catheter. Not CE marked; not available for sale in Europe.
- Map-iT Diagnostic Catheters Portfolio of differentiated high-quality diagnostic EP catheters acquired through Access Point Technologies. Proprietary designs with quality materials and refined manufacturing deliver performance and durability for treating complex arrhythmias.
Quantifiable outcome
- Over 150,000 patients treated globally with robotic technology
- +4 more outcomes
Companies that use Stereotaxis
Customer profileNamed customers10 records
Segments1 record
Ideal customer profiles1 record
Stereotaxis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability5 records
Feature9 records
Stereotaxis partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- RobocathcoreStereotaxis acquiring Robocath, a France-based surgical robot developer, for up to $45 million ($20M upfront + $25M contingent). Robocath develops R-One+ robotic technology for interventional cardiology and neurointerventions - the only robot commercially available in Europe for PCI. Expected to close mid-2026, operating as subsidiary.
- CardioFocusmajorCollaboration to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. Joint effort aims to accelerate commercialization of combined robotic PFA system, with preclinical testing showing promising results.
- Access Point Technologies (APT)coreStereotaxis acquired Access Point Technologies, a Minnesota-based developer and manufacturer of electrophysiology catheters. Transaction closed July 31, 2024. Acquisition enhances in-house catheter manufacturing capabilities, contributing approximately $5 million in annual revenue.
- AbbottcoreGlobal collaboration combining Abbott's leading cardiac mapping systems (EnSite X, Ensite X EP System, AcQMap) with Stereotaxis' advanced robotic magnetic navigation technology. First integrated procedures completed in US at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
- Shanghai MicroPort EP Medtech Co. Ltd.majorStrategic relationship with Shanghai MicroPort EP Medtech Co. Ltd. for China market expansion. China described as new 'geographic pillar' for commercial efforts. MicroPort joint venture with Robocath formed CathBot for vascular intervention robotics.
- Osypka AGmajorBroad strategic collaboration with Osypka AG for designing and developing next-generation magnetic ablation catheter to be navigated using Stereotaxis' robotic technology.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Stereotaxis competitors and assessment
Company assessmentDirect peers
- Robocath: French developer of the R-One+ robotic system for percutaneous coronary interventions — being acquired by Stereotaxis in 2026 for up to $45M. Most directly comparable peer as it operates in the same endovascular surgical robotics category with an overlapping customer base of interventional cardiologists.
Broad incumbents
- Biosense Webster (Johnson & Johnson): Dominant EP franchise inside J&J offering CARTO 3 electroanatomical mapping and a broad ablation catheter portfolio. Comparable as it sets the standard for EP lab workflows that Stereotaxis must integrate with rather than replace, and represents the largest competitive threat in cardiac ablation.
- Abbott: Major cardiac mapping and ablation player with EnSite X system, and a global collaboration partner with Stereotaxis. Comparable because it both competes and integrates with Stereotaxis robotic systems in EP labs globally, defining much of the workflow ecosystem.
- Boston Scientific: Large EP franchise with Rhythmia mapping and a leading RF and PFA ablation catheter portfolio. Comparable as a broad incumbent in cardiac ablation whose procedural workflow, mapping, and catheter choices compete for the same hospital capital and per-procedure budget as Stereotaxis.
- Medtronic: Cardiac rhythm and ablation incumbent with its own cryoablation and PFA platforms. Comparable as a broad EP and cardiac device incumbent competing for the same hospital accounts and ablation procedure volumes.
Emerging players
- Acutus Medical: Developer of the AcQMap non-contact mapping system, which has been demonstrated in integrated procedures with Stereotaxis robotic navigation. Comparable as an emerging EP mapping player whose system competes for mapping share within the same lab where Stereotaxis robots operate.
- CardioFocus: Pulsed Field Ablation specialist partnered with Stereotaxis to develop a robotic PFA system. Comparable as a focused emerging player in next-gen ablation whose technology will be navigated by Stereotaxis systems, making it a co-development partner and adjacent competitor in PFA.
- Catheter Precision: Developer of the VIVO non-invasive arrhythmia localization technology, integrated with Stereotaxis RMN. Comparable as a small-cap emerging EP technology company whose products are designed to plug into the same robotic navigation workflows.
- inHEART: Provider of AI-derived preoperative 3D mapping from CT/MRI integrated with Stereotaxis robotic navigation. Comparable as a niche emerging player whose mapping output feeds into the same robotic ablation procedures.
Regional players
- MicroPort Scientific: Shanghai MicroPort EP Medtech is Stereotaxis's China distribution and strategic partner, and parent of the CathBot vascular robotics JV with Robocath. Comparable as a regional EP and surgical robotics player with overlapping technology and customer base in the China market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Stereotaxis social profiles
Digital presenceStereotaxis compliance and trust
Trust signalCompliance3 records
Stereotaxis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stereotaxis leadership team
Management profileNumber of profiles
Profiles1 record
Stereotaxis subsidiaries and ownership
Company hierarchySubsidiaries2 records
Stereotaxis funding detail
Funding detailFunding overview
Funding rounds10 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stereotaxis M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stereotaxis
What does Stereotaxis do?
Stereotaxis develops and sells Robotic Magnetic Navigation (RMN) systems—Genesis and GenesisX—that use computer-controlled magnetic fields to navigate electrophysiology catheters inside the heart with precision and stability. The company also sells proprietary single-use ablation and mapping catheters (MAGiC, MAGiC Sweep, Map-iT) used in conjunction with the robotic systems, as well as the Synchrony digital surgery platform and SynX cloud connectivity app. These offerings are sold primarily to hospitals and cardiac electrophysiology labs for minimally invasive treatment of arrhythmias and coronary artery disease.
Is Stereotaxis a public or private company?
Stereotaxis is a public company. It is classified as public and is currently operating.
When was Stereotaxis founded?
Stereotaxis was founded in 1990. It employs 51 to 100 people.
Where is Stereotaxis based?
Stereotaxis is headquartered in St Louis, United States, in the North America region.
How does Stereotaxis make money?
Four revenue lines are on record. Robotic Surgical Systems are the primary driver. The others are catheter Consumables, digital Surgery Software/Services and stock Sales (ATM Facility).
Who are Stereotaxis's main competitors?
Robocath is listed as a direct peer. Broad incumbents are Biosense Webster (Johnson & Johnson), Abbott, Boston Scientific and Medtronic. Emerging players are Acutus Medical, CardioFocus, Catheter Precision and inHEART. MicroPort Scientific is listed as a regional player.
Does Stereotaxis have an API?
No public API is recorded for Stereotaxis.
What industry is Stereotaxis in?
Stereotaxis's product category is Surgical Robotics for Cardiac Electrophysiology. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HDAAAIAC, Healthcare & Assistive Robotics. Its NAICS code is 334510 and its SIC code is 3845.